I-mab Biopharma (Hangzhou) Co., Ltd. announced that it will receive equity funding for $19 million from returning investor I-Mab on February 7, 2024. The transaction is expected to be close by the end of March 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 USD | +2.16% | +1.65% | -2.63% |
Apr. 18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
Apr. 15 | I-Mab Announces Chief Medical Officer Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.63% | 149M | |
+30.54% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+14.72% | 239B | |
+9.74% | 210B | |
-7.40% | 200B | |
+8.12% | 167B | |
-1.42% | 161B |
- Stock Market
- Equities
- IMAB Stock
- News I-Mab
- I-mab Biopharma Co., Ltd. announced that it expects to receive CNY 19 million in funding from I-Mab